Get the Stockscreener App
3.09
3.13%
-0.10
After Hours:
3.17
0.08
+2.59%
Tharimmune Inc stock is traded at $3.09, with a volume of 554.82K.
It is down -3.13% in the last 24 hours and up +29.29% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$3.19
Open:
$3.19
24h Volume:
554.82K
Relative Volume:
0.42
Market Cap:
$108.29M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.2431
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
+3.34%
1M Performance:
+29.29%
6M Performance:
+66.13%
1Y Performance:
+47.14%
1-Day Range:
$2.95
$3.27
1-Week Range:
$2.84
$3.56
52-Week Range:
$0.952
$9.08
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
3.09 | 111.79M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tharimmune Inc Stock (THAR) Latest News
Breakout Zone: Is Tharimmune Inc stock attractive for income investorsRecession Risk & Safe Capital Growth Trade Ideas - moha.gov.vn
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors - Burlington Free Press
What technical signals suggest for Tharimmune Inc. stockJuly 2025 Chart Watch & Safe Entry Momentum Stock Tips - Улправда
Can Tharimmune Inc. stock hit record highs again2025 Stock Rankings & AI Forecast Swing Trade Picks - Улправда
Is Tharimmune Inc. stock attractive for income investorsJuly 2025 Action & Free High Accuracy Swing Entry Alerts - Bölüm Sonu Canavarı
Will Tharimmune Inc. stock benefit from AI adoptionWeekly Trend Report & High Conviction Trade Alerts - DonanımHaber
THAR SEC FilingsTharimmune Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Tharimmune (NASDAQ:THAR) Stock Price Down 5.9%What's Next? - MarketBeat
Is Tharimmune Inc. stock attractive for ETFs2025 Fundamental Recap & Weekly Return Optimization Alerts - DonanımHaber
How Tharimmune Inc. stock performs in rising dollar environmentJuly 2025 Opening Moves & Community Verified Trade Alerts - DonanımHaber
Sentiment Recap: Can Tharimmune Inc. stock weather global recession2025 AllTime Highs & Capital Protection Trade Alerts - Улправда
Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network - marketscreener.com
DTCC move to tokenize $30T in Treasuries—and why one biotech cares - Stock Titan
DTCC partners with Digital Asset to tokenize US Treasury securities - Investing.com
Tharimmune (THAR) outlines 176,934,358-share PIPE resale and Canton Coin strategy - Stock Titan
Tharimmune (NASDAQ: THAR) seeks approval for new directors, warrants and 7M-share equity plan boost - Stock Titan
Tharimmune appoints Jacob Asbury as new CFO - MSN
Tharimmune Appoints Jacob Asbury as Chief Financial Officer - citybiz
Tharimmune Appoints Jacob Asbury as New CFO - TipRanks
Tharimmune, Inc. Appoints New Chief Financial Officer - TradingView — Track All Markets
Tharimmune (NASDAQ: THAR) names Jacob Asbury CFO with new employment agreement - Stock Titan
Tharimmune appoints Jacob Asbury as chief financial officer - Investing.com
Tharimmune (NASDAQ: THAR) appoints ex‑Clear Street CFO Asbury to guide Canton Coin treasury build‑out - Stock Titan
Why Tharimmune Inc. stock remains a top recommendation2025 Market WrapUp & Free Real-Time Market Sentiment Alerts - Newser
How buybacks impact Tharimmune Inc. stock value2025 EndofYear Setup & Daily Risk Controlled Trade Plans - Newser
Tharimmune (NASDAQ: THAR) details agent change in $64,910,161 stock plan - Stock Titan
How Tharimmune Inc. stock reacts to Fed rate cutsPortfolio Gains Report & Consistent Income Trade Ideas - Newser
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - The Holland Sentinel
Will Tharimmune Inc. stock benefit from infrastructure spendingInsider Buying & Technical Entry and Exit Tips - Newser
Is Tharimmune Inc. stock attractive for growth ETFsEarnings Recap Summary & High Return Stock Watch Alerts - Newser
Tharimmune (THAR) Stock Analysis Report | Financials & Insights - Benzinga
Can Tharimmune Inc. stock weather global recessionMarket Trend Report & AI Enhanced Trade Execution Alerts - BỘ NỘI VỤ
Reviewing Tharimmune (NASDAQ:THAR) and Ventyx Biosciences (NASDAQ:VTYX) - Defense World
‘We refused to do an ICO’: The truth behind Canton’s tokenomics - TradingView — Track All Markets
Tharimmune Raises $545 Million in Private Placement to Acquire Canton Coin and Expand Blockchain Adoption - Global Legal Chronicle
What drives Tharimmune Inc stock priceSmall Cap Stock Opportunities & Build Capital Safely - earlytimes.in
Tharimmune Shares Jump After FDA Signals Support for TH104 Modeling Plan - MSN
Crypto Company Creates Bizarre Drug - Futurism
Tharimmune Stock Plummets -46% With 9-Day Losing Streak - Trefis
Using Bollinger Bands to evaluate Tharimmune Inc.Gap Up & Expert Curated Trade Setups - newser.com
Will Tharimmune Inc. stock benefit from sector rotationPortfolio Performance Report & Free Accurate Trade Setup Notifications - newser.com
Why analysts upgrade Tharimmune Inc. stockJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - newser.com
How resilient is Tharimmune Inc. stock in market downturnsWatch List & Trade Opportunity Analysis Reports - newser.com
Is Tharimmune Inc. stock a buy for dividend growthTrade Exit Summary & Stepwise Swing Trade Plans - newser.com
What insider trading reveals about Tharimmune Inc. stock2025 Momentum Check & Safe Capital Growth Tips - newser.com
Is Tharimmune Inc. stock attractive for retirement portfoliosWeekly Gains Report & Capital Efficiency Focused Strategies - newser.com
Will Tharimmune Inc. stock deliver long term returnsInsider Selling & Verified Momentum Stock Alerts - newser.com
What the charts say about Tharimmune Inc. todayMarket Risk Report & Pattern Based Trade Signal System - newser.com
Will earnings trigger a reversal in Tharimmune Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com
Using data models to predict Tharimmune Inc. stock movementWeekly Investment Summary & Accurate Buy Signal Alerts - newser.com
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):